Member Info for NathanBryce

An enormous potential market.

This has got to be good! http://www.biospace.com/news_story.aspx?StoryID=470682&full=1

Opti tweet: "Neurologist Speaks Out About the Importance of Gut Health for Prevention and Treatment of “Incurable” Neurological Disorders" http://beforeitsnews.com/alternative/2017/09/neurologist-speaks-out-about-the-importance-of-gut-health-for-prevention-and-treatment-of-incurable-neurological-disorders-3551440.html

More from TW on twitter: "Oh Ye of little faith!. There was big news on Tuesday for Optibiotix (OPTI). This was ONE of the big deals we were waiting for. There are more to follow but this should send critics of Optibiotix scuttling for cover as India's Tata is a giant. It has 660,000 employees and annual sales of $103.51 billion! Those who doubted us as we bought our first shares for two years HERE - at sub 55p a few weeks ago you can apologise. now. Go form an orderly queue. The shares are now 75p-77.5p and they are GOING MUCH HIGHER & SOON!" Make of this what you will.

Top-Table stuff!

And a few interesting weeks ahead, I suspect. GLA

This has now gone as high as 79.15, and is selling at 77.3.

Buys now going through at 76.8.

The interview can be accessed via Twitter - search @OptiBiotix "O'Hara.. talks about the potential for 39 RNS’s that could be announced over the coming months as opportunities turn to fruition.

'High Commercial Interest Turning To Fruition' http://www.***************************/interview-optibiotix-health-plc-high-commercial-interest-turning-fruition/412733582

'Snowball' is right. And if the snowball gets big enough, evenually you get an avalanche. And they tend to occur suddenly and unexpectedly.

Optibiotix tweets today: Following the market launch of LP-LDL, HLH order another 200,000 units within 2 weeks for German pharmacies

Sorry - wrong board!

I am about to BLOW OFF!! etc. etc.

Especially Masterbaker, whose research and optimism have been, and continue to be, an insipiration to all!

Wonder if our friend Thompson will have anything to say in this week's IC that might give a fillip to this wilting flower?

Shares Magazine, 8th January 2015 rates SiS as 'Buy', with a full page article, and analyst (Santam Securities) price target of 83p.

Apologies - that should, of course, read "hope for".

"Oxfordshire -based Lombard Medical Technologies has achieved what most pharmaceutical cope for every year but often fail to deliver - US Food & Drug Administration approval. It has got sign-off for Aorfix, which works like scaffolding to support weak arteries in the abdominal area."

With Lombard presenting at the 32nd Charing Cross Symposium 9th-12th April I would anticipate results being published in the week commencing 11th April?